Acceptability of Hepatitis B Vaccination in General Population
Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hepatitis B
Intervention: Data collection (Other)
Phase: N/A
Status: Completed
Sponsored by: GlaxoSmithKline Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline
Summary
The present study is conducted in order to assess the acceptability of Hepatitis B
vaccination in French general population before and after reimbursement of the paediatric
vaccine InfanrixHexa. Four measurements are planned, first before reimbursement and the
others at year 1, 2 and 3 after reimbursement.
Clinical Details
Official title: Measurement of the Changes in Hepatitis B Immunization Coverage in Infants, and the Acceptability Thereof, Before Reimbursement, Then During the Three Years After Reimbursement of InfanrixHexa® in France, Among the General Population
Study design: Observational Model: Family-Based, Time Perspective: Cross-Sectional
Primary outcome: Proportion of infants receiving Hepatitis B vaccination.
Secondary outcome: Evaluation of the immunization coverage levels by other vaccines.Acceptability of vaccinating against Hepatitis B.
Detailed description:
The present study aims to evaluate the changes in Hepatitis B immunization coverage and the
acceptability thereof among parents, in the general population. This is a national,
prospective, epidemiological study, comprising four measurement time-points over a
three-year period, (T1 in 2009, T2 in 2010, T3 in 2011, and T4 in 2012) in order to cover
the period prior to the introduction of InfanrixHexa® reimbursement, the transition period,
and the period following reimbursement of the vaccine. The periods between each data
collection time-point will be identical, lasting a year. Two age groups will be investigated
at each data collection time-point: 12-15 months and 24-27 months, thus providing
measurements before/after reimbursement.
Eligibility
Minimum age: 12 Months.
Maximum age: 27 Months.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Infants aged 12 to 15 months or 24 to 27 months inclusive at the time of the study.
- With a parent or legal representative agreeing to take part in the interview.
- Residing in metropolitan France.
Exclusion Criteria:
- Refusal to take part.
- Infants having lived in another country in their first two years of life.
Locations and Contacts
Additional Information
Starting date: May 2009
Last updated: January 31, 2013
|
